全文获取类型
| 收费全文 | 24828篇 |
| 免费 | 2304篇 |
| 国内免费 | 823篇 |
专业分类
| 耳鼻咽喉 | 227篇 |
| 儿科学 | 754篇 |
| 妇产科学 | 690篇 |
| 基础医学 | 2491篇 |
| 口腔科学 | 218篇 |
| 临床医学 | 2611篇 |
| 内科学 | 3168篇 |
| 皮肤病学 | 370篇 |
| 神经病学 | 1531篇 |
| 特种医学 | 903篇 |
| 外国民族医学 | 1篇 |
| 外科学 | 4163篇 |
| 综合类 | 3340篇 |
| 现状与发展 | 2篇 |
| 一般理论 | 3篇 |
| 预防医学 | 2046篇 |
| 眼科学 | 369篇 |
| 药学 | 2681篇 |
| 16篇 | |
| 中国医学 | 939篇 |
| 肿瘤学 | 1432篇 |
出版年
| 2024年 | 55篇 |
| 2023年 | 374篇 |
| 2022年 | 632篇 |
| 2021年 | 1084篇 |
| 2020年 | 897篇 |
| 2019年 | 894篇 |
| 2018年 | 842篇 |
| 2017年 | 958篇 |
| 2016年 | 938篇 |
| 2015年 | 950篇 |
| 2014年 | 1502篇 |
| 2013年 | 2067篇 |
| 2012年 | 1391篇 |
| 2011年 | 1561篇 |
| 2010年 | 1324篇 |
| 2009年 | 1240篇 |
| 2008年 | 1232篇 |
| 2007年 | 1196篇 |
| 2006年 | 1140篇 |
| 2005年 | 1014篇 |
| 2004年 | 884篇 |
| 2003年 | 776篇 |
| 2002年 | 591篇 |
| 2001年 | 543篇 |
| 2000年 | 435篇 |
| 1999年 | 373篇 |
| 1998年 | 326篇 |
| 1997年 | 285篇 |
| 1996年 | 286篇 |
| 1995年 | 227篇 |
| 1994年 | 209篇 |
| 1993年 | 154篇 |
| 1992年 | 160篇 |
| 1991年 | 154篇 |
| 1990年 | 122篇 |
| 1989年 | 118篇 |
| 1988年 | 114篇 |
| 1987年 | 101篇 |
| 1986年 | 89篇 |
| 1985年 | 124篇 |
| 1984年 | 97篇 |
| 1983年 | 86篇 |
| 1982年 | 69篇 |
| 1981年 | 67篇 |
| 1980年 | 63篇 |
| 1979年 | 52篇 |
| 1978年 | 45篇 |
| 1977年 | 26篇 |
| 1976年 | 31篇 |
| 1973年 | 14篇 |
排序方式： 共有10000条查询结果，搜索用时 31 毫秒
1.
目的通过Meta分析评价安宁疗护对社区临终患者生活质量的影响。方法计算机检索PubMed、CINAHL、ScienceDirect、MEDLINE、Cochrane Library、SAGE数据库、中国知网、维普中文科技期刊数据库、万方数据库和中国生物医学文献数据库中安宁疗护对社区临终患者的随机对照试验,由2名研究人员独立筛选文献并提取资料,对符合质量标准的随机对照试验进行Meta分析。结果共纳入7篇文献,包括1095名社区临终患者。Meta分析结果显示,安宁疗护可以改善社区临终患者的总体生活质量(SMD=0.48,95%CI0.07~0.88,P=0.02)和情绪功能(SMD=1.27,95%CI0.59~1.95,P<0.001),在改善生活质量的躯体功能、角色功能、认知功能和社会功能水平上差异无统计学意义(P>0.05)。结论安宁疗护能改善社区临终患者的总体生活质量和情绪功能,但对生活质量其他功能的改善情况还需要设计更加规范、多中心、大样本的随机对照试验进一步证实。 相似文献
2.
目的探究肿瘤坏死因子-α(Tumornecrosis factor-α,TNF-α)-308基因对导管相关性脓毒症(Catheter related sepsis,CRS)患者病情的影响,旨在为临床治疗CRS提供科学依据。方法选取2017年7月-2018年10月于浙江大学医学院附属杭州市第一人民医院接受治疗的86例CRS患者为研究对象,按照是否并发多器官功能障碍综合征将患者分为试验组和对照组,对照组共48例,未并发多器官功能障碍综合征,试验组共38例,并发多器官功能障碍综合征,分析两组患者TNF-α-308基因多态性差异,使用多因素Logistic回归分析CRS患者并发多器官功能障碍综合征的危险因素。结果试验组GA基因型频率34.21%、AA基因型频率50.00%、高G等位基因频率18.42%均高于对照组,GG基因型频率52.63%、A等位基因频率28.95%均低于对照组,差异均具有统计学意义(P<0.05);多因素Logistic回归分析结果显示,低GG基因型频率、低G等位基因频率、高GA基因型频率、高AA基因型频率、高A等位基因频率是CRS患者并发多器官功能障碍综合征的危险因素(P<0.05)。结论TNF-α-308基因与CRS患者病情密切相关,GG基因型频率和G等位基因频率降低,GA基因型频率、AA基因型频率、A等位基因频率升高会加重患者的病情,增加多器官功能障碍综合征的发生风险,临床上应该加以重视。 相似文献
3.
4.
5.
6.
7.
Shafqat R. Chaudhry Ilana S. Lendvai Sajjad Muhammad Philipp Westhofen Johannes Kruppenbacher Lukas Scheef Henning Boecker Dirk Scheele Rene Hurlemann Thomas M. Kinfe 《Brain stimulation》2019,12(3):643-651
Objective
To assay peripheral inter-ictal cytokine serum levels and possible relations with non-invasive vagus nerve stimulation (nVNS) responsiveness in migraineurs.Methods
This double-blinded, sham-controlled study enrolled 48 subjects and measured headache severity, frequency [headache days/month, number of total and mild/moderate/severe classified attacks/month], functional state [sleep, mood, body weight, migraine-associated disability] and serum levels of inflammatory markers [inter-ictal] using enzyme-linked immunoassays at baseline and after 2 months of adjunctive nVNS compared to sham stimulation and suitably matched controls.Results
No significant differences were observed at baseline and after 2 months for headache severity, total attacks/month, headache days/month and functional outcome [sleep, mood, disability] between verum and sham nVNS. However, the number of severe attacks/month significantly decreased in the verum nVNS group and circulating pro-inflammatory IL-1β was elevated significantly in the sham group compared to nVNS. Levels of anti-inflammatory IL-10 were significantly higher at baseline in both groups compared to healthy controls, but not at 2 months follow-up [p?<?0.05]. Concentrations of high-mobility group box-1 (HMGB-1), IL-6, tumor-necrosis factor-α (TNF-α), leptin, adiponectin, ghrelin remained unchanged [p?>?0.05]. No severe device-/stimulation-related adverse events occurred.Conclusion
2 months of adjunctive cervical nVNS significantly declined the number of severe attacks/month. Pro-inflammatory IL-1β plasma levels [inter-ictal] were higher in sham-treated migraine patients compared to verum nVNS. However, pro- [IL-6, HMGB-1, TNF-α, leptin] and anti-inflammatory [IL-10, adiponectin, ghrelin] mediators did not differ statistically. Profiling of neuroinflammatory circuits in migraine to predict nVNS responsiveness remains an experimental approach, which may be biased by pre-analytic variables warranting large-scale biobank-based systematic investigations [omics]. 相似文献8.
9.
Marta López-Fauqued Laura Campora Frédérique Delannois Mohamed El Idrissi Lidia Oostvogels Ferdinandus J. De Looze Javier Diez-Domingo Thomas C. Heineman Himal Lal Janet E. McElhaney Shelly A. McNeil Wilfred Yeo Fernanda Tavares-Da-Silva 《Vaccine》2019,37(18):2482-2493
Background
The ZOE-50 (NCT01165177) and ZOE-70 (NCT01165229) phase 3 clinical trials showed that the adjuvanted recombinant zoster vaccine (RZV) was ≥90% efficacious in preventing herpes zoster in adults. Here we present a comprehensive overview of the safety data from these studies.Methods
Adults aged ≥50 (ZOE-50) and ≥70 (ZOE-70) years were randomly vaccinated with RZV or placebo. Safety analyses were performed on the pooled total vaccinated cohort, consisting of participants receiving at least one dose of RZV or placebo. Solicited and unsolicited adverse events (AEs) were collected for 7 and 30?days after each vaccination, respectively. Serious AEs (SAEs) were collected from the first vaccination until 12?months post-last dose. Fatal AEs, vaccination-related SAEs, and potential immune-mediated diseases (pIMDs) were collected during the entire study period.Results
Safety was evaluated in 14,645 RZV and 14,660 placebo recipients. More RZV than placebo recipients reported unsolicited AEs (50.5% versus 32.0%); the difference was driven by transient injection site and solicited systemic reactions that were generally seen in the first week post-vaccination. The occurrence of overall SAEs (RZV: 10.1%; Placebo: 10.4%), fatal AEs (RZV: 4.3%; Placebo: 4.6%), and pIMDs (RZV: 1.2%; Placebo: 1.4%) was balanced between groups. The occurrence of possible exacerbations of pIMDs was rare and similar between groups. Overall, except for the expected local and systemic symptoms, the safety results were comparable between the RZV and Placebo groups irrespective of participant age, gender, or race.Conclusions
No safety concerns arose, supporting the favorable benefit-risk profile of RZV. 相似文献10.